Single-centre open-label prospective study, enrolling 128 children and adolescents aged 6-17
years, who receive medication for ADHD of any subtype (presentation). Long-term results are
evaluated with tests of ADHD symptoms (Qb-test), intellectual ability (Wechsler scales;
WISC), adaptive functioning (Vineland scale), everyday functioning (Weiss Functional
Impairment Scale; WIFRS), and quality of life (Child Health and Illness Profile-Child Edition
Scale; CHIP-CE) during 24 months of ADHD treatment.